The No. 1 Trade Show Site in the U.S.

Menu
×
EVENT DATE
Jun 2016
M T W T F S S
27282930
EXPO DATE
Jun 2016
M T W T F S S
27282930

Venue


Online Event
Location map
Tel:
Type: Online Event

HOTEL DEALS

Booking.com

TRAVEL DEALS

Expedia.com

Partners

exhibitus success by design Remington Hotels

Webinar on A Second Look at 510(k) Changes

B2B 1

EVENT DESCRIPTION

Overview: 

The topic is 510(k) changes, a topic that is still producing more than its share of 483's and warning letters. In general, FDA does not return filings because the change described in them is not sufficiently "significant", and only rarely suggests that the traditional 510(k) should at least be scaled down to a special 510(k).

Therefore, it is up to the sponsor/manufacturer to determine whether this change will be significant or not. The decision has to be made by the manufacturer, subject to review by the FDA inspector. This talk will provide quality and regulatory personnel the means to help to the company make the right decision and document it fully, before the change goes through.

Why should you Attend: Failure to file a 510(k) for a change to a product which has already been cleared under 510(k) is one of the more frequent complaints in 483's and in warning letters. The result of this finding is the requirement to file a 510(k) for a product that is on the market, and usually, to file a 510(k) and have the change cleared before the product can be marketed with the change. In general, FDA will not insist on recalling product with the change already in the market unless they decide there is a safety issue, but even so, this means disruption of the manufacturing (already producing the changed product) and marketing for the product. The best approach is to understand what FDA means by a "significant change" and document completely the reasons why you believe the change does not warrant a filing. 

Areas Covered in the Session:

  • Background: the regulation
  • Guidance and FDA expectations
  • Concrete examples
  • Analysis (consecutive changes)and checklist
  • Documentation

Who Will Benefit:

  • QA and RA specialists
  • QA and RA managers

Speaker Profile:
Anna Longwell is currently principal attorney of the Palo Alto Law firm, Longwell and Associates, which specializes in Food and Drug law. The firm has expertise in US FDA expectations, regulation and law, affecting the development and ultimate marketing of new medical products, drugs, devices and biologics. They have served the regulatory needs of large (>$2 billion/year) divisions of Fortune 500 companies, and small (4 person) biotech start-ups. 

Contact Detail:

Compliance4All DBA NetZealous,
Phone: +1-800-447-9407
Email: support@compliance4All.com
http://www.compliance4all.com/
Event Link : http://bit.ly/510k_changes
LinkedIn Like us
Twitter Follow us
Facebook Like us

Not sure if you want to exhibit at or attend the Webinar on A Second Look at 510(k) Changes? See the panels below to get the information you need to make an informed decision.

EVENT CONTACTS

Sign Up for FULL Membership and Log In to access Event Contact Information.

EVENT DETAILS

Primary Industry:
Manufacturing - General
Other Industries:
Manufacturing, Manufacturing - General
Audience:
QA and RA specialists
QA and RA managers
Notes:
Show Owner:
Sponsorship:

Exhibitor Information +

Booth Details:

Booth Size
Booth Cost
No exhibiting.
Amenities
Electricity:
n/a
Water:
n/a
Generator:
n/a
Marketing Vehicles Allowed:
n/a
Services
n/a

floor plan

MORE events +

BUSINESS+
HEALTH CARE+
MANUFACTURING+
TECHNOLOGY+

Display Makers

Promo Makers

2017: 2,575 Trade Shows
2018: 575 Trade Shows
© copyright since 2008 All Rights Reserved eventsinamerica.com
952
page views